Guardant Health (GH) Stock Looks Below Fair Value On A Huge Run

Guardant Health has turned into a dramatic long term story for shareholders, yet the real question now is whether the current US$158.60 price can be supported by the cash flows its business is expected to produce. With the stock sharply higher over several years and new clinical and regulatory developments landing, the focus has shifted to what the Discounted Cash Flow (DCF) view of its intrinsic value suggests about that price.

• Over the past 3 years the share price has risen by very large multiple terms, which puts a lot of weight on whether Guardant Health's cash generation can eventually grow into the current valuation.
• Recent wins for Guardant360 CDx in Europe and expanded liquid biopsy use in screening and melanoma monitoring can influence expectations for future revenue scale, margins and the timing of when operations might fund themselves rather than relying on ongoing cash burn and legal outlays.
• What if you looked at Guardant Health through its sales instead? See why Guardant Health's 18.0x P/S tells a different valuation story.

For investors, the debate is whether the current share price is adequately explained by Guardant Health's projected cash flows when valued using a Discounted Cash Flow (DCF) intrinsic value lens.

Guardant Health is one way to play the precision oncology and liquid biopsy story, yet it often helps to compare that thesis with other 33 healthcare AI stocks

Is Guardant Health a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) approach here looks at what Guardant Health might deliver to shareholders in future free cash flow and compares that to today’s US$158.60 share price. Latest twelve month free cash flow sits at a loss of about US$232.9 million, so the model leans heavily on a recovery story rather than steady current profitability.

Analyst projections in the DCF point to free cash flow shifting from these losses to growing positive figures over the next decade, which implies a business that needs scale before the cash engine really starts working. Because the U.S. Patent Trial and Appeal Board upheld TwinStrand’s patent and confirmed damages and ongoing royalties, that legal overhang helps explain why the market might still be cautious even though the DCF projections put Guardant Health's estimated intrinsic value meaningfully above the current share price. Find out what Guardant Health could be worth using our Discounted Cash Flow (DCF) estimate.

The Guardant Health Narrative: What Would Justify Today's Price?

Narratives for Guardant Health pick up where the DCF puzzle leaves off and explain which potential paths for revenue growth, profitability and earnings would need to occur for the stock to appear meaningfully cheaper or more expensive than it does today. All of this is available on Simply Wall St's Community page. Instead of providing a single output, each narrative details the assumptions that underpin its view of fair value so you can compare those expectations with actual results over time.

Guardant Health has sparked two very different read throughs, with one camp seeing more upside in the story than the other.

Bull case: 20% undervalued

"Rapid integration of AI-powered clinical analytics and multi-omic profiling into Guardant's Smart Liquid Biopsy platform is creating new clinical applications, enhancing product utility and differentiation versus peers..."

Discover why this Narrative puts Guardant Health at 20% undervalued.

Bear case: 5% overvalued

"Reliance on premium Medicare ADLT pricing for Shield at US$1,495 and very limited commercial reimbursement means any shift in payer mix toward commercial patients or slower than hoped contracting could compress Shield ASPs and limit revenue growth from screening..."

Explore why this Narrative puts Guardant Health at 5% overvalued.

Guardant Health's valuation still leaves one crucial piece of the puzzle unanswered

Cash flows and scenarios tell only part of the Guardant Health story, because the people steering the business and how their incentives are set can heavily influence what happens next for shareholders. See who runs Guardant Health and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com